Loading
Blood tests can now find leftover cancer months before scans, but most patients who test positive have nothing to enrol in. One standing trial per country would fix that.
MRD-guided intervention has proved feasible in bladder cancer and colorectal cancer, but each trial rebuilds the same infrastructure: assay contracts, testing schedules, referral pathways and consent. A standing national platform (one master protocol, shared control arm, rolling arms contributed by any sponsor, registry-based follow-up) converts a scattered set of underpowered studies into a permanent engine for the MRD setting.
Shares IMvigor011, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment.
Shares AI trial matching & clinical decision support, Basket, umbrella, and platform trials, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.
Shares CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Dormant cells and minimal residual disease.
Shares IMvigor011, DYNAMIC, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
Shares AI trial matching & clinical decision support, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Basket, umbrella, and platform trials, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Cancer Research UK, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Cancer Research UK, Trial design, endpoints and cost.